It is importantto note that JAK2 mediates the signaling of cytokinessuch as granulocyte colony-stimulating factor and erythropoietin,which regulate myelopoiesis and erythropoiesis; therefore, its systemicinhibition is associated with adverse effects such as neutropenia,anemia, and thrombocytopenia. Hence,the topical delivery of PROTACs represents a promising strategy tomodulate JAK2 locally in the skin, with the potential to avoid systemichematological side effects. The gene discussed is JAK2; the disease is neutropenia.